KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
OnAugust 10, 2017, KemPharm, Inc., a Delaware corporation, or KemPharm, issued a press release announcing its corporate and financial results for the quarter endedJune 30, 2017, as well as information regarding a conference call and live webcast presentationto discuss these corporate and financial results. A copy of the press release and presentationare furnished as Exhibits 99.1 and99.2, respectively,to this Current Report on Form 8-K.The information contained in the press release and presentationfurnished as Exhibits 99.1 and 99.2, respectively,shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of KemPharm’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
|
ExhibitNo. |
Description |
|
99.1 |
Press Release titled “KemPharm, Inc.ReportsSecond Quarter 2017 Results”datedAugust 10, 2017. |
| 99.2 | Presentation titled "Second Quarter 2017 Results" datedAugust 10, 2017. |
KEMPHARM, INC ExhibitEX-99.1 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm EXHIBIT 99.1 KemPharm,…To view the full exhibit click here
About KemPharm, Inc. (NASDAQ:KMPH)
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
